- Home
- PDCC vs CHRS Comparison
PDCC vs CHRS Comparison
Compare PDCC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDCC
- CHRS
- Stock Information
- Founded
- PDCC N/A
- CHRS 2010
- Country
- PDCC
- CHRS United States
- Employees
- PDCC N/A
- CHRS N/A
- Industry
- PDCC
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDCC
- CHRS Health Care
- Exchange
- PDCC NYSE
- CHRS Nasdaq
- Market Cap
- PDCC 135.4M
- CHRS 134.4M
- IPO Year
- PDCC N/A
- CHRS 2014
- Fundamental
- Price
- PDCC $20.08
- CHRS $1.07
- Analyst Decision
- PDCC
- CHRS Strong Buy
- Analyst Count
- PDCC 0
- CHRS 4
- Target Price
- PDCC N/A
- CHRS $5.38
- AVG Volume (30 Days)
- PDCC N/A
- CHRS 2.0M
- Earning Date
- PDCC N/A
- CHRS 03-12-2025
- Dividend Yield
- PDCC N/A
- CHRS N/A
- EPS Growth
- PDCC N/A
- CHRS N/A
- EPS
- PDCC N/A
- CHRS N/A
- Revenue
- PDCC N/A
- CHRS $304,340,000.00
- Revenue This Year
- PDCC N/A
- CHRS $2.07
- Revenue Next Year
- PDCC N/A
- CHRS N/A
- P/E Ratio
- PDCC N/A
- CHRS N/A
- Revenue Growth
- PDCC N/A
- CHRS 44.19
- 52 Week Low
- PDCC N/A
- CHRS $0.66
- 52 Week High
- PDCC N/A
- CHRS $2.65
- Technical
- Relative Strength Index (RSI)
- PDCC N/A
- CHRS 39.03
- Support Level
- PDCC N/A
- CHRS $1.06
- Resistance Level
- PDCC N/A
- CHRS $1.16
- Average True Range (ATR)
- PDCC 0.00
- CHRS 0.08
- MACD
- PDCC 0.00
- CHRS 0.00
- Stochastic Oscillator
- PDCC 0.00
- CHRS 5.56
About PDCC PEARL DIVER CREDIT COMPANY INC
PEARL DIVER CREDIT COMPANY INC is a non-diversified closed ended management investment company.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.